Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV

Inclusion criteria

• Aged 2 months (60-70 days) on the day of inclusion into the study
• Born at full term pregnancy ( over 36 weeks) with a birth weight ≥ 2.5 kg 2Ibs) or more
• Parent(s) or legal representative able to understand and give authorization and sign informed consent for participation
• Able to attend all planned clinic appointment and obey and follow all study instructions

Exclusion criteria

• Taking part in another clinical trial during the 4 weeks before the first trial vaccination
• Have plans to take part in another clinical trial d during this trial period
• Inborn or acquired decreased body natural defense, undertaking treatment that can reduce body's natural defense such as cancer drugs, radiation in the past six months or long term corticosteroid treatment
• Systemic reaction to any vaccine component or history of life-threatening reaction to study vaccine or any vaccine with the same ingredient(s)
• Prolonged or long time illness that could interfere with study or full participation
• Received blood or blood-derived products since birth
• Received any vaccine in the 4 weeks before the first trial vaccination is given (except BCG and hepatitis B)
• Have plans to receive any vaccine in the 4 weeks after the (or any) study vaccination is given (except DTacP)
• Previous vaccination against the poliomyelitis infection with the trial vaccine or another vaccine
• History of poliomyelitis infection (confirmed either by symptoms, blood or other laboratory test)
• Clinical or serological evidence of systemic illness including hepatitis B, hepatitis C or Human immunodeficiency virus (HIV)
• Bleeding disorder or a low platelet which do not allow vaccination into the muscle
• Had seizures in the past
• Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of inclusion